CenExel Clinical Research, Inc.

CenExel Clinical Research is a leading, privately held clinical research site network dedicated to supporting the life sciences industry in discovering and developing life-changing therapies. Headquartered in Salt Lake City, Utah, the company's mission is to advance global healthcare by delivering high-quality clinical research and innovative trial solutions, ultimately improving patient outcomes.

The company provides specialized clinical research expertise, offering services that span the full trial lifecycle, including patient recruitment, screening, enrollment, medical procedures, monitoring, protocol development, clinical trial operations, and data collection. CenExel operates a nationwide network of 18 Centers of Excellence, focusing on a wide array of therapeutic areas such as clinical pharmacology, early phase studies, central nervous system (CNS) disorders (including Alzheimer's, Parkinson's, depression, and schizophrenia), metabolic research, post-operative pain, vaccine research, dermatology, ethnic bridging studies, and psychedelics.

In recent leadership changes, Dr. Sy Pretorius was appointed Chief Executive Officer, effective May 1, 2026. CenExel has recently undertaken strategic expansions across its sites in Tampa, Denver, Anaheim, Toms River, and Atlanta, enhancing capabilities in various therapeutic areas and adding new facilities. The company also formed a Pain Task Force in June 2026 to innovate research approaches for next-generation, non-opioid pain therapies. CenExel is backed by private equity firms BayPine and Webster Equity Partners, with BayPine acquiring a majority stake in a transaction expected to close in the second quarter of 2025. The company is recognized for its scientific expertise, world-class Principal Investigators, advanced patient engagement strategies, premium data, and integrated operational excellence, having conducted thousands of studies and over 10,000 clinical trials with 100,000 patients since its inception.